Marinomed Biotech AG is a biopharmaceutical development company focusing on the development of innovative therapies based on patent protected technology platforms. Products against respiratory viruses derived from the proprietary MAVIREX© platform are marketed globally with renowned partners. The new MARINOSOLV® platform enables novel stable aqueous formulations of hardly soluble compounds such as corticosteroids, allowing a faster onset of action and a and a better bioavailability.
R&D:Marinomed has a track record of success with products already marketed internationally and several follow-on compounds in development. The new patent protected MARINOSOLV® platform enables novel stable aqueous formulations of hardly soluble compounds such as but not limited to corticosteroids, allowing a faster onset of action and a better bioavailability. Please contact us for further information. MARINOSOLV® might solve your drug formulation problem.
Production:Marinomed has outsourced production and manufacturing to first class renowned partners. All Carragelose® containing products are part of an anti-viral OTC product portfolio targeting the common cold and influenza-like illnesses and treat viral infections of the respiratory tract. The products are launched in several European as well as non-European countries. Details at: www.carragelose.com
Sales/Distribution:Marinomed products are distributed and sold via partnerships with internationally renowned companies. For details visit: www.carragelose.com/
Veterinärplatz 1
1210 Vienna
Vienna
Contact: Renate Moser (PhD, BD&L)
Telephone: +43 (1) 2507744-60
Email: office@marinomed.com
Website